US Supreme Court to Hear Landmark Roundup Weedkiller Case, Bayer Faces Major Legal Challenge

The US Supreme Court has agreed to hear a landmark lawsuit concerning whether Roundup, one of the world’s most widely used herbicides, causes cancer. The decision marks a pivotal moment in the ongoing legal challenges facing Bayer AG and Monsanto, which Bayer acquired in 2018, according to The New York Times.

Roundup has been one of the best-selling herbicides globally since its introduction in 1974. Over the past several years, tens of thousands of plaintiffs have sued Monsanto/Bayer, alleging that prolonged exposure to glyphosate, the active ingredient in Roundup, caused them to develop non-Hodgkin lymphoma and other cancers. Bayer has already lost multiple lawsuits in US courts, resulting in billions of dollars in damages.

The central question before the Supreme Court is whether the Environmental Protection Agency’s (EPA) determination of glyphosate’s safety should preempt state-level tort litigation. If the Court rules in favor of federal regulatory preemption, it would significantly limit state courts’ jurisdiction over such cases, which would be a major victory for Bayer. Conversely, if the Court sides with the plaintiffs, Bayer will face additional litigation and substantial compensation claims.

Since acquiring Monsanto, Bayer has paid over $10 billion in Roundup-related settlements and damages. Company leadership has repeatedly stated that Roundup’s safety has been affirmed by numerous regulatory agencies worldwide, including the EPA and the European Chemicals Agency (ECHA).

Environmental organizations and plaintiffs’ attorneys counter that there is a significant divergence between independent scientific research and industry-funded studies in assessing glyphosate’s carcinogenicity. The International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” in 2015, a classification that has served as a key basis for many lawsuits.

The Supreme Court will hear oral arguments from both sides in the coming months, with a ruling expected by late 2026. The decision will not only shape Bayer’s future but also have profound implications for America’s environmental regulatory framework and chemical liability laws.

Source: The New York Times